Related Experiment Videos
Essential thrombocythemia in a child: management with anagrelide
M M Chintagumpala1, C P Steuber, D H Mahoney
1Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
The American Journal of Pediatric Hematology/Oncology
|January 1, 1991
Summary
Essential thrombocythemia (ET) is a rare pediatric blood disorder. Anagrelide effectively managed symptoms and improved platelet function in an 11-year-old boy with ET.
Area of Science:
- Pediatric Hematology
- Oncology
Background:
- Essential thrombocythemia (ET) is a rare myeloproliferative neoplasm.
- Pediatric ET cases are infrequently reported, presenting unique diagnostic and management challenges.